

24 **Abstract:**

25 Type 2 diabetes (T2DM) is a major cause of morbidity and mortality globally. Carnosine, a naturally
26 occurring dipeptide, has anti-inflammatory, antioxidant, and anti-glycating effects, with preliminary
27 evidence suggesting it may improve important chronic disease risk factors in adults with
28 cardiometabolic conditions. In this randomized controlled trial, 43 adults (30%F) living with
29 prediabetes or T2DM consumed carnosine (2 grams) or a matching placebo daily for 14 weeks to
30 evaluate its effect on glucose metabolism assessed via 2 hr, 75g oral glucose tolerance test. Secondary
31 outcomes included body composition analysis by dual energy x-ray absorptiometry (DEXA), calf
32 muscle density by pQCT and anthropometry. Carnosine supplementation decreased blood glucose at 90
33 minutes (-1.31mmol/L; p=0.02) and 120 minutes (-1.60mmol/L, p=0.02) and total glucose area under
34 the curve (-3.30mmol/L; p=0.04) following an oral glucose tolerance test. There were no additional
35 changes in secondary outcomes. The carnosine group results remained significant before and after
36 adjustment for age, sex, and change in weight (all>0.05), and in further sensitivity analyses accounting
37 for missing data. There were no significant changes in insulin levels. Likely mechanisms may include
38 changes to hepatic glucose output explaining the observed reduction in blood glucose without changes
39 in insulin secretion following carnosine supplementation. This study provides preliminary support for
40 larger trials evaluating carnosine as a potential treatment for prediabetes and the early stages of T2DM.

41

42 **Introduction:**

43 Type 2 diabetes (T2DM) continues to place an immense burden on healthcare systems globally¹. The
44 World Health Organization (WHO) estimates that over the last 40 years, the number of people with
45 diabetes has increased from 108 million to 451 million and will increase to 693 million by 2045^{1,2}. This
46 rapid increase has cemented diabetes as a leading cause of mortality³ and a major contributor to burden
47 of disease globally⁴ and a leading cause of mortality³. Diabetes increases the risk of all-cause mortality
48 by 2-3 times⁵ and contributes to as much as 80% of all premature deaths caused by non-communicable
49 disease⁵. It is also an immense economic burden, with \$760 billion USD spent globally on diabetes and
50 its complications in 2019 alone⁵. This is projected to rise to \$825 billion by 2030 and \$845 billion by
51 2045⁵.

52 Due to its significant healthcare and societal burden, effective management of T2DM is critical.
53 The principal aims of management of T2DM are to lower and stabilize blood glucose levels, which
54 decreases the incidence and severity of microvascular and macrovascular complications, improves
55 quality of life, and reduces mortality⁶. More than 120 million people with diabetes worldwide are
56 prescribed metformin as their main therapy, making it the most broadly used glucose-lowering
57 medication globally⁷. Other medications used include dipeptidyl peptidase 4 (DPP4) inhibitors, sodium-
58 glucose co-transporter 2 (SGLT2) inhibitors, sulfonylureas, and the glucagon like peptide (GLP-1)
59 receptor agonists⁸. These medications are hampered by adverse events, including hypoglycemic
60 episodes, with resultant sequelae, and some cannot be prescribed in patients with common diabetic
61 comorbidities, such as severe chronic renal disease⁹. This makes the identification of safe and effective
62 means to better control glucose an ongoing priority for researchers.

63 Carnosine, anserine, and ophidine/balenine, a group of naturally occurring histidine containing
64 dipeptides (HCD), are present in large amounts in the skeletal muscle and brain of mammals¹⁰⁻¹⁴.
65 Carnosine has several physiological activities in humans, being a potent antioxidant, and metal chelator
66 as well as anti-inflammatory, and anti-glycating effects^{14,15}. Carnosine supplementation has been shown
67 to improve glycemic control and insulin levels in adults with prediabetes and diabetes¹⁶⁻¹⁹, and it also

68 has a positive effect on the blood lipidome by maintaining levels of trihexosylceramide and
69 phosphatidylcholine and free cholesterol levels^{17,20-22}.

70 However, studies investigating the role of carnosine in glucose metabolism are limited by small
71 numbers of participants, frequently treated concomitantly with a variety of glucose-lowering
72 medications as well as a lack of randomized placebo-controlled studies of participants with overweight
73 or obese. Therefore, our aim was to evaluate the effect of a 14-week carnosine supplement regimen for
74 T2DM and make direct measurements of glucose metabolism in adults with prediabetes or T2DM. We
75 hypothesize that oral carnosine supplementation for 14 weeks would improve glucose metabolism and
76 reduce insulin levels in patients with prediabetes or T2DM compared to placebo. A recent systematic
77 review and meta-analysis of 20 studies determined that b-alanine, a precursor to carnosine, had no effect
78 on body composition in athletes²³, however it is unknown whether it has any effect in patients with
79 cardiometabolic disease. In our trial, we aim to utilize DXA to further elucidate the effect of carnosine
80 supplementation on whole body mass, fat percentage, fat mass and fat free mass in group of individuals
81 with overweight but not obese.

82 **Methods:**

83 *Study design:*

84 The study was a parallel-group double-blinded randomized control trial (RCT). Informed written
85 consent was provided by all participants before commencing the trial. The trial was registered at
86 clinicaltrials.gov (NCT02917928), and was conducted according to the Standardized Protocol
87 Interventions: Recommendations for Interventional trials²⁴ and followed the CONSORT guidelines²⁵ .
88 The study was approved by Monash Health ethics committee (Ref: 16061A). and conforms to the
89 Declaration of Helsinki²⁶.

90

91

92 *Sample size:*

93 The sample size of the study was calculated using the G-Power software, with blood glucose
94 concentrations via oral glucose tolerance test as the primary outcome. Data from a sub-study in this trial
95 on subjects with overweight or obesity²⁷, and our trial in a cohort of participants with overweight or
96 obesity¹⁶, and from a study of subjects with diabetes by our group(ref); who had mean HbA1c of 7 and
97 fasting glucose of 10 was considered in the calculation. A sample size of 22 in each arm was required
98 to detect a 20% change in fasting glucose and absolute change of 0.5 in HBA1c for 80% power, with
99 target recruitment set to 50 participants based on a type I error of 0.05 (two-tailed)²⁸. A 20% change in
100 insulin sensitivity was selected based on evidence of similar improvement in insulin sensitivity when
101 treated with troglitazone, an hypoglycemic medication and insulin sensitiser²⁷.

102 *Study population:*

103 To be eligible, participants were required to be aged 18-70 years. All participants had pre-diabetes or
104 T2DM diagnosed by OGTT (according to the WHO guidelines) and were untreated, or taking only
105 metformin. Participants were excluded if their HbA1c was 8% or higher or had changed their
106 medications in the past 3 months. Participants had to have BMI less than 40 kg/m² and a stable body
107 weight (no more than 5kg above or below the current weight over the last 12 months). Participants were
108 otherwise without diagnosis of any renal, cardiovascular, hematological, respiratory, gastrointestinal,
109 or central nervous system disease, and not pregnant or lactating. Participants were not required to
110 change their diets or routine physical activity but were not included if they consumed more than 4
111 standard drinks per week for men and 2 standard drinks per week for women or if they smoked.
112 Recruited participants were required to remain on the same medications during the 14-week trial. The
113 participant would be discontinued from the study if their HbA1c became greater than 8% and a
114 medication change was stipulated by their medical practitioner at any stage of the study.

115 *Recruitment, Intervention and Randomization*

116 Participants were recruited through advertising via poster, radio, email newsletters and newspapers.
117 Interested participants were first contacted via phone and completed a screening eligibility
118 questionnaire. Potentially eligible participants were then invited for a screening visit, where they were
119 assessed against the inclusion and exclusion criteria, underwent anthropometry and a screening OGTT
120 test at the Clinical Trials Centre of the Monash Health Translational Research Precinct. Eligible
121 participants were randomized to intervention or placebo; the randomization used block sizes of 4 by
122 sex, using computer-generated randomization codes sent to the clinical trials pharmacy by the study
123 statistician. The carnosine group were asked to take 2g of carnosine (Flamma Group, 1g twice daily
124 including the study days) and the placebo group received an equivalent amount of methylcellulose (1g
125 twice daily) for 14 weeks. Medication was dispensed in indistinguishable capsules and containers to
126 ensure participants and researchers were blinded to the group allocation. Participants were asked to
127 inform the trial doctor of any adverse events as they arose and the trial doctor followed up with all
128 participants at the end of the trial to discuss these. Participants were asked to return the treatment
129 containers at the end of the study to assess treatment compliance. Compliance was evaluated by
130 counting number of unconsumed capsules and dividing by number of capsules provided.

131 *Outcomes:*

132 The primary outcome was plasma glucose level on 2-hour oral glucose tolerance test (OGTT).
133 Secondary measures included HbA1c, insulin levels, body composition, calf muscle density, and
134 anthropometric parameters. All outcomes were measured at baseline and repeated after 14-weeks of
135 intervention.

136 *Anthropometric, biochemical and body composition assessment*

137 The study physician collected participants' medical history in person and performed a physical
138 examination. This included collecting anthropometric data using a digital scale (Tanita BWB-600) and
139 standing stadiometer, and vital signs collected via Omron digital blood pressure monitor (Model: BBP-
140 742). Waist and hip measurements were measured using a measuring tape at the midpoint between the

141 upper iliac crest and the lowest rib, and at the widest part of the buttocks. Participants' bloods were
142 collected after an overnight fast of at least 10 hours using aseptic methods, and analyzed by the National
143 Association of Testing Authorities accredited Monash Health pathology service, which operates an
144 automated core laboratory at Monash Medical Centre Clayton.

145 Whole-body dual-energy x-ray absorptiometry (DXA; Hologic Discovery A, Hologic, USA) was used
146 to estimate fat and lean mass. The DXA scanner was calibrated daily with the manufacturer's spine
147 phantom and the short-term intra-individual coefficient of variation (CV) for lean and fat mass was
148 1.60% and 2.67%, respectively. All DXA scans were analyzed by the same investigator.

149 A single 2.5 mm transverse peripheral quantitative computed tomography (pQCT) scan (Stratec
150 XCT3000, Stratec Medizintechnik GmbH, Pforzheim, Germany) at a speed of 20 mm/s and voxel size
151 of 0.8 mm was obtained at 66% of the tibial length of the non-dominant leg. The length of the tibia was
152 determined by measuring the distance between the prominence of the medial malleolus and the tibial
153 plateau. A planar scout view of the distal tibia was used to locate scan sites, and reference lines were
154 placed parallel to the distal joint surface of the tibia. Calf muscle density (mg/cm^3 ; density of tissue
155 within the muscle compartment after removal of subcutaneous fat and bone) was estimated using
156 manufacturer's algorithms and software (version 6.2). Scans were analyzed using a smoothing filter
157 (F03F05) at a threshold of $41 \text{ mg}/\text{cm}^3$. The device was calibrated daily using the manufacturer's
158 phantom and the short-term intra-individual CV for muscle density was 1.2%. All pQCT scans were
159 analyzed by one individual. Adverse events while participating in the 14-week intervention period were
160 recorded in the progress notes as they arose and were reviewed with the chief investigator at the start
161 of every year while preparing the trial progress reports.

162 *Glucose and insulin assessment*

163 Participants completed a 2-hour OGTT following overnight fasting. The OGTT drink containing 75g
164 of glucose was consumed within 5 minutes after which bloods were collected aseptically into tubes
165 (Serum Separation Tubes – SST II) at 30-minute intervals (0, 30, 60, 90, 120 mins). After centrifugation,

166 the serum samples were stored at -80°C until analysis. Serum samples at all the time points were
167 measured for glucose and insulin, with the values also used to calculate the area under the curve (AUC)
168 by the trapezoidal method. The homeostatic model assessment of HOMA-IR (insulin resistance),
169 HOMA- β (steady state β -cell function %) and HOMA-S% (Insulin sensitivity) were also calculated as
170 described previously^{16,28,29}.

171 *Statistical Analysis*

172 Statistical analysis was performed with the statistical softwares JASP (v0.16.3), and SPSS (v29.0.0.0).
173 Parametric data were reported as mean and standard deviations and non-parametric data were reported
174 as median and interquartile range. Skew was assessed by Shapiro-Wilk testing, with skewed data
175 logarithmically transformed with satisfactory transformation assessed by evaluation of residual plots.
176 Continuous variables were analyzed using Analysis of Covariance (ANCOVA) adjusted for baseline
177 values. Additional ANCOVA was performed with diabetes (prediabetes vs T2DM) status, obesity status
178 (BMI > 30) or metformin intake as covariates to evaluate interaction effects. All tests were two-tailed,
179 and alpha level of significance was set at 0.05. The primary analysis was performed on a complete case
180 protocol; however, an additional sensitivity analysis was performed with multiple imputation on
181 missing cases was performed. Missing data was imputed with predictive mean matching, with a total
182 of five imputations modelled. The resulting data sets were analyzed as above, with the pooled mean and
183 standard error of the imputations, and the range of the resulting p-values reported.

184 **Results:**

185 A total of 88 participants were assessed for eligibility, with 49 eligible for enrolment and
186 randomization. A total of 43 participants (13 women years and 30 men completed the trial at 14 weeks
187 (23 placebo and 20 carnosine). Of 43, 22 participants were assessed as pre-diabetic and 21 as diabetic
188 based on their screening OGTT. Five participants were lost to follow-up (Two placebo, three carnosine),
189 and one additional participant was withdrawn after initiating treatment with an additional medication
190 following randomization (Figure 1). Baseline participant data is presented in table 1.

191 **Effect of carnosine supplementation on obesity measures**

192 After the 14-week intervention, we detected a decrease in BMI of 0.74 kg/m² (p=0.048) in the carnosine
193 group compared to placebo; but this did not remain significant when adjusting for diabetes status,
194 obesity status or by metformin intake, and did not show any interaction effects with these variables.
195 There were no differences in body weight, waist circumference or waist-to-hip ratio, body fat
196 percentage (BF%), fat mass and fat free mass between the groups (all p>0.05) (Table 2. There were no
197 interaction effects with diabetes status, obesity status or by metformin intake.

198 **Effect of carnosine supplementation on glycemic measures**

199 Carnosine supplementation reduced glucose levels at 90-minutes (-1.60 mmol/L, p=0.018) and 120-
200 minutes (-1.40 mmol/L, p=0.016), as well as glucose AUC (-3.30 mmol/L, p= 0.04) compared to
201 placebo controls (Table 2, Figure 2). There were no changes in any other glucose or insulin measures,
202 insulin AUC, HOMA-S, HOMA-β or HOMA-IR (all p>0.05) (table 2). There was no interaction
203 between changes in any of the variables and diabetic status, obesity status or by metformin intake. The
204 glucose results remained consistent in sensitivity analysis evaluating the effect of missing data
205 imputation (Table 3).

206 Carnosine supplementation did not result in any adverse events, with the only reported adverse event
207 being pain and mild bruising at the site of venipuncture in one participant. Overall, compliance was
208 excellent (100%) with all participants consuming all capsules given to them.

209 **Discussion:**

210 In our randomized controlled study, we showed that carnosine supplementation for 14 weeks reduced
211 90 and 120-minute glucose levels after OGTT, and reduced glucose AUC. There were otherwise no
212 significant changes to body composition, nor other glucometabolic measures. Given carnosine is safe,
213 cost effective³⁰, and available over the counter in most countries, the reductions in glucose levels make
214 carnosine an attractive agent for the management of prediabetes and diabetes, and warrants further
215 large-scale trials to evaluate its long-term effects in the prevention and treatment of T2DM.

216 In this trial, the reduction of 3.3 mmol/L in glucose AUC following a OGTT represents a 7.2% decrease
217 in glucose response, which is likely to provide clinically significant outcomes in both preventing
218 transition from prediabetes and in diabetic complications, particularly given 40% of the cohort was
219 already using metformin³¹. In the Diabetes Prevention Program Outcomes Study (DPPOS), participants
220 with prediabetes who returned to normoglycemia had 56% lower risk of diabetes than those who
221 remained prediabetic³². Similarly, our recent meta-analysis pooling 23 interventional studies showed
222 improvement in glycemic control for participants with both type 1 and T2DM, following carnosine
223 supplementation leading to improvement of fasting glucose (mean difference (MD) [95% CI]= -0.6
224 mmol/L [-1.1, -0.1], p=0.03 and HbA1c (MD [95% CI]= -0.5% [-0.4,-0.6], p<0.001) ³³. In the meta-
225 analysis, sensitivity analyses eliminating studies in which fasting glucose was elevated at baseline, still
226 favored supplementation with carnosine³³, aligning with the results from the present study. We and
227 others also highlighted that there was insufficient data to evaluate whether carnosine supplementation
228 improved glucose following OGTT^{33,34}, although some showed glucose lowering effects in people with
229 diabetes ¹⁷. While our findings of improved glucose control after OGTT align with these findings, our
230 study did not show changes in HbA1c levels or fasting glucose ^{35,36}. This is potentially due to differences
231 in participants, with our study investigating people with pre-diabetes and relatively well-controlled
232 T2DM. Additionally, the 14-week intervention in this study may have been too short to cause an
233 appreciable change in HbA1c, which typically requires longer to decrease. While the evidence provided
234 in this study has demonstrated an effect of carnosine supplementation on glucose concentrations, the
235 mechanisms underpinning this are unclear. The glucose-lowering effect was in the absence of an
236 alteration in insulin concentrations, as well as indirect measures of insulin sensitivity, which further
237 highlighted the differences in baseline insulin levels between the placebo and treatment groups (2.7
238 mIU/ml vs 4.1mIU/ml); is a possible reason as to why a significant change in insulin at 14 weeks was
239 not detected. This may indicate decreased hepatic glucose output a potential mediator of the effect seen
240 in this trial.

241 Carnosine is rapidly hydrolyzed by serum carnosinase to its constituents b-alanine and histidine.
242 Carnosine's poor bioavailability in humans is highlighted by the fact that individuals with CNBP1

243 genotype characterized by low serum carnosinase activity are often afflicted by carnosinemia³⁷,
244 however carnosinemia can be induced by intake³⁷. The high variation in serum carnosinase activity
245 seems a natural variation and depends upon the polymorphism of the CNDP1 genotype inherited.

246 Although our study found a decrease of 0.74 kg/m² in BMI in the carnosine group (p=0.045) after 14-
247 week supplementation compared to the placebo; with no significant change in weight between follow-
248 up and baseline, this is unlikely to be clinically relevant, and is potentially random. Our study found no
249 change in waist circumference or waist-to-hip ratio after carnosine supplementation, in line with
250 previous studies of similar cohorts^{16,23}. Liu et al³⁶ reported in one trial that carnosine as part of a
251 combined supplement with cinnamon and chromium increased lean mass, which is in contrast to our
252 trial. Although, our study cohort was largely overweight rather than obese and several participants had
253 been pretreated with metformin and/or diet control and exercise, which could explain the lack of effect
254 observed in these measures. Another meta-analysis³³, also found a significant 3.5cm decrease in waist
255 circumference, findings not seen here. A prior RCT³⁸ compared β -alanine (BA) supplementation only
256 (n=8) (the rate-limiting precursor to carnosine and a preferred method to increase muscle carnosine
257 levels by circumventing serum carnosinase activity), creatine only (n=8) and BA plus creatine (n=7) or
258 placebo (n=7) for 28 days along with a structured exercise routine in a group of physically active
259 females³⁸. They found that despite addition of exercise, there were no reductions in body weight, fat
260 mass, body fat and fat-free mass³⁸ in any cohort; findings echoed in another trial of β -alanine and
261 exercise combined³⁹. Another recent meta-analysis of 426 participants found no effect of
262 supplementation on any measure of body composition, and no interaction effects resulting from
263 resistance training, endurance training or combined training²³. This data, and ours provides evidence
264 that neither carnosine nor β -alanine supplementation seems to affect body composition directly, with or
265 without complimentary exercise in adults without obesity. However, it should be noted that most of
266 these studies were in athletes who are less likely to show large changes in body composition. Further
267 trials which supplement carnosine in individuals with obesity may better elucidate an effect of carnosine
268 on body composition.

269 The findings of the current study agree with previous work demonstrating that carnosine has glucose-
270 lowering effects in individuals with impaired glucose tolerance, however, our data was unable to
271 demonstrate any changes in insulin levels as found in other similar trials^{16,40}, possibly due to the large
272 number of participants with diabetes being treated with metformin in our cohorts or the fact that we
273 used indirect measurements for insulin sensitivity and secretion. We have shown previously that
274 carnosine supplementation leads to increases in insulin sensitivity and secretion in individuals with
275 overweight and obesity¹⁶. Future studies will need to employ gold-standard euglycemic-
276 hyperinsulinemic clamp and intravenous glucose tolerance test to accurately evaluate carnosine's effect
277 on these measures.

278 Chronic inflammation, oxidative stress and advanced glycation end products (AGE) and advanced lipid
279 peroxidation end products (ALE) have all been implicated in the pathogenesis of diabetes and its
280 complications^{41,42}. Carnosine is thought to improve glycemic control at least in part via anti-AGE action
281 by preventing the formation of cross-linked proteins by methylglyoxal (MG) and neutralizing it^{43,44}.
282 Free sugars undergo a series of biochemical changes⁴⁵ resulting in their oxidization after which they
283 covalently bond to proteins²⁵. These modified proteins form permanent cross-linkages with oxidized
284 sugars and other proteins over time to form AGEs, which through activation of immune processes,
285 contribute to worsening hyperglycaemia^{46,47}. Carnosine has been proposed to improve a range of
286 cardiovascular, dyslipidemic, and inflammatory outcomes^{15,17,48} – all essential for the care of patients
287 with diabetes. This adds additional benefits to the use of carnosine as a part of treatment of T2DM,
288 particularly in the light of the glucose lowering effect demonstrated here. The analysis of inflammatory
289 and lipid profiles collected as part of this trial is currently being analysed and will be reported in another
290 article.

291 **Strengths, Limitations, and future direction**

292 While this study was methodologically robust, there are some limitations We used surrogate measures
293 of insulin sensitivity and secretion HOMA-IR HOMA-S and HOMA- β which are not as sensitive as the
294 gold-standard methods. Our analysis showed that the baseline insulin level for the carnosine group was

295 29.8% higher than the baseline insulin for the placebo group. This random characteristic as well as
296 missing OGTT and insulin data for a few participants (table 2) may have further obscured the detection
297 of a significant change in insulin levels after 14 weeks, even though the carnosine group lowered
298 HOMA-IR scores to greater degree than the placebo group (change of -1.4 mIU/ml vs -0.18 mIU/ml),
299 although these results were not stastically significant. The higher insulin level in the carnosine group at
300 baseline may have been a reason why a larger therapeutic change was evident after treatment. Moreover,
301 the trial was limited by a smaller sample size due to the difficulty in recruiting participants with
302 prediabetes and T2DM treated with metformin only and furthermore by COVID-19 pandemic which
303 halted the trial for several months. Another limitation was the relatively short follow-up period, which
304 left questions surrounding treatment durability unanswered.

305 **Conclusion**

306 A 14-week regimen of carnosine supplementation reduced glucose concentrations following OGTT in
307 patients with prediabetes and diabetes but had no effect on insulin concentrations or obesity measures.
308 While this makes carnosine a promising candidate in the management of T2DM, further randomized
309 controlled trials of carnosine supplementation for cardiometabolic conditions are warranted,
310 particularly in the light of carnosine's additional protective benefits to cardiovascular and inflammatory
311 outcomes relevant to diabetes^{33,49}.

312 **Acknowledgements**

313 We acknowledge Flamma Group for providing carnosine for the trial and Ms. Josphine Johnson, Dr.
314 Estifanos Baye, Ms Paula Fudge-Larsen and Dr. Martin Schonn for their assistance with data collection.
315 We also acknowledge funding agencies including CASS and Royal Australasian College of Physicians
316 foundations. Also, we thank volunteers Dr. Aylin Hilberath, Dr. Dilek Tuncel, Dr. Lachlan B McMillan
317 and Dr. Mavil May Cervo for their assistance.

318 **Conflicts of Interest:**

319 The authors report no conflicts of interest.

320

321 **References**

322

- 323 1. Lin X, Xu Y, Pan X, et al. Global, regional, and national burden and trend of diabetes in 195
324 countries and territories: an analysis from 1990 to 2025. *Scientific Reports*.
325 2020;10(1):14790.
- 326 2. Cho NH, Shaw J, Karuranga S, et al. IDF Diabetes Atlas: Global estimates of diabetes
327 prevalence for 2017 and projections for 2045. *Diabetes research and clinical practice*.
328 2018;138:271-281.
- 329 3. Li J, Tong Y, Zhang Y, et al. Effects on All-cause Mortality and Cardiovascular Outcomes in
330 Patients With Type 2 Diabetes by Comparing Insulin With Oral Hypoglycemic Agent Therapy:
331 A Meta-analysis of Randomized Controlled Trials. *Clinical Therapeutics*. 2016;38(2):372-
332 386.e376.
- 333 4. Liu J, Ren Z-H, Qiang H, et al. Trends in the incidence of diabetes mellitus: results from the
334 Global Burden of Disease Study 2017 and implications for diabetes mellitus prevention. *BMC*
335 *Public Health*. 2020;20(1):1415.
- 336 5. Williams R, Karuranga S, Malanda B, et al. Global and regional estimates and projections of
337 diabetes-related health expenditure: Results from the International Diabetes Federation
338 Diabetes Atlas, 9th edition. *Diabetes Research and Clinical Practice*. 2020;162.
- 339 6. van den Arend IJM, Stolk RP, Krans HMJ, Grobbee DE, Schrijvers AJP. Management of type 2
340 diabetes: a challenge for patient and physician. *Patient Education and Counseling*.
341 2000;40(2):187-194.
- 342 7. Cetin M, Sahin S. Microparticulate and nanoparticulate drug delivery systems for metformin
343 hydrochloride. *Drug Delivery*. 2016;23(8):2796-2805.
- 344 8. McCoy RG, Dykhoff HJ, Sangaralingham L, et al. Adoption of new glucose-lowering
345 medications in the US—the case of SGLT2 inhibitors: nationwide cohort study.
346 2019;21(12):702-712.
- 347 9. Nauck MA, Wefers J, Meier JJTLD, Endocrinology. Treatment of type 2 diabetes: challenges,
348 hopes, and anticipated successes. 2021;9(8):525-544.
- 349 10. Crush K. Carnosine and related substances in animal tissues. *Comparative biochemistry and*
350 *physiology*. 1970;34(1):3-30.
- 351 11. Kohen R, Yamamoto Y, Cundy KC, Ames BN. Antioxidant activity of carnosine,
352 homocarnosine, and anserine present in muscle and brain. *Proceedings of the National*
353 *Academy of Sciences*. 1988;85(9):3175-3179.
- 354 12. Peters V, Klessens CQF, Baelde HJ, et al. Intrinsic carnosine metabolism in the human kidney.
355 *Amino Acids*. 2015;47(12):2541-2550.
- 356 13. Matthews JJ, Artioli GG, Turner MD, Sale C. The physiological roles of carnosine and β -
357 alanine in exercising human skeletal muscle. *Medicine & Science in Sports & Exercise*.
358 2019;51(10):2098-2108.
- 359 14. Baye E, Ukropcova B, Ukropec J, Hipkiss A, Aldini G, de Courten B. Physiological and
360 therapeutic effects of carnosine on cardiometabolic risk and disease. *Amino Acids*.
361 2016;48(5):1131-1149.
- 362 15. Feehan J, Hariharan R, Buckenham T, et al. Carnosine as a potential therapeutic for the
363 management of peripheral vascular disease. 2022.
- 364 16. de Courten B, Jakubova M, de Courten MP, et al. Effects of carnosine supplementation on
365 glucose metabolism: Pilot clinical trial. *Obesity*. 2016;24(5):1027-1034.
- 366 17. Houjehani S, Kheirouri S, Faraji E, Jafarabadi MA. L-Carnosine supplementation attenuated
367 fasting glucose, triglycerides, advanced glycation end products, and tumor necrosis factor- α

- 368 levels in patients with type 2 diabetes: a double-blind placebo-controlled randomized clinical
369 trial. *Nutrition Research*. 2018;49:96-106.
- 370 18. Elbarbary NS, Ismail EAR, El-Naggar AR, Hamouda MH, El-Hamamsy M. The effect of 12
371 weeks carnosine supplementation on renal functional integrity and oxidative stress in
372 pediatric patients with diabetic nephropathy: a randomized placebo-controlled trial. *Pediatr*
373 *Diabetes*. 2018;19(3):470-477.
- 374 19. Nealon R, Sukala W, Coutts R, Zhou S. The effect of 28 days of beta-alanine supplementation
375 on exercise capacity and insulin sensitivity in individuals with type 2 diabetes mellitus: a
376 randomised, double-blind and placebo-controlled pilot trial. *J Nutr Sci Res*. 2016;1(3):1-7.
- 377 20. Baye E, Ukropec J, de Courten MPJ, et al. Effect of carnosine supplementation on the plasma
378 lipidome in overweight and obese adults: a pilot randomised controlled trial. *Scientific*
379 *Reports*. 2017;7(1):17458.
- 380 21. Erion DM, Park HJ, Lee HY. The role of lipids in the pathogenesis and treatment of type 2
381 diabetes and associated co-morbidities. *BMB Rep*. 2016;49(3):139-148.
- 382 22. Parhofer KG. Interaction between Glucose and Lipid Metabolism: More than Diabetic
383 Dyslipidemia. *Diabetes Metab J*. 2015;39(5):353-362.
- 384 23. Ashtary-Larky D, Bagheri R, Ghanavati M, et al. Effects of beta-alanine supplementation on
385 body composition: a GRADE-assessed systematic review and meta-analysis. *Journal of the*
386 *International Society of Sports Nutrition*. 2022;19(1):196-218.
- 387 24. Chan A-W, Tetzlaff JM, Gøtzsche PC, et al. SPIRIT 2013 explanation and elaboration:
388 guidance for protocols of clinical trials. *Bmj*. 2013;346.
- 389 25. Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: Updated Guidelines for
390 Reporting Parallel Group Randomized Trials. *Annals of Internal Medicine*. 2010;152(11):726-
391 732.
- 392 26. World Medical Association Declaration of Helsinki: ethical principles for medical research
393 involving human subjects. *Jama*. 2013;310(20):2191-2194.
- 394 27. Menon K, Cameron JD, de Courten M, de Courten B. Use of carnosine in the prevention of
395 cardiometabolic risk factors in overweight and obese individuals: study protocol for a
396 randomised, double-blind placebo-controlled trial. *BMJ open*. 2021;11(5):e043680-e043680.
- 397 28. Baye E, Menon K, de Courten MPJ, Earnest A, Cameron J, de Courten B. Does
398 supplementation with carnosine improve cardiometabolic health and cognitive function in
399 patients with pre-diabetes and type 2 diabetes? study protocol for a randomised, double-
400 blind, placebo-controlled trial. *BMJ Open*. 2017;7(9):e017691.
- 401 29. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis
402 model assessment: insulin resistance and β -cell function from fasting plasma glucose and
403 insulin concentrations in man. *Diabetologia*. 1985;28(7):412-419.
- 404 30. Menon K, de Courten B, Magliano DJ, Ademi Z, Liew D, Zomer E. The Cost-Effectiveness of
405 Supplemental Carnosine in Type 2 Diabetes. *Nutrients*. 2022;14(1):215.
- 406 31. Riedel AA, Heien H, Wogen J, Plauschinat CA. Loss of Glycemic Control in Patients with Type
407 2 Diabetes Mellitus Who Were Receiving Initial Metformin, Sulfonylurea, or
408 Thiazolidinedione Monotherapy. *Pharmacotherapy: The Journal of Human Pharmacology*
409 *and Drug Therapy*. 2007;27(8):1102-1110.
- 410 32. Perreault L, Pan Q, Mather KJ, Watson KE, Hamman RF, Kahn SE. Effect of regression from
411 prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results
412 from the Diabetes Prevention Program Outcomes Study. *The Lancet*. 2012;379(9833):2243-
413 2251.
- 414 33. Menon K, Marquina C, Liew D, Mousa A, de Courten B. Histidine-containing dipeptides
415 reduce central obesity and improve glycaemic outcomes: A systematic review and meta-
416 analysis of randomized controlled trials. *Obesity Reviews*. 2020;21(3):e12975.

- 417 34. Matthews JJ, Dolan E, Swinton PA, et al. Effect of Carnosine or β -Alanine Supplementation
418 on Markers of Glycemic Control and Insulin Resistance in Humans and Animals: A Systematic
419 Review and Meta-analysis. *Advances in Nutrition*. 2021;12(6):2216-2231.
- 420 35. Elbarbary NS, Ismail EAR, El-Naggar AR, Hamouda MH, El-Hamamsy M. The effect of 12
421 weeks carnosine supplementation on renal functional integrity and oxidative stress in
422 pediatric patients with diabetic nephropathy: a randomized placebo-controlled trial.
423 *Pediatric Diabetes*. 2018;19(3):470-477.
- 424 36. Liu Y, Cotillard A, Vatier C, et al. Correction: A Dietary Supplement Containing Cinnamon,
425 Chromium and Carnosine Decreases Fasting Plasma Glucose and Increases Lean Mass in
426 Overweight or Obese Pre-Diabetic Subjects: A Randomized, Placebo-Controlled Trial. *Plos*
427 *one*. 2015;10(12):e0145315.
- 428 37. Everaert I, Taes Y, Heer ED, et al. Low plasma carnosinase activity promotes carnosinemia
429 after carnosine ingestion in humans. *American Journal of Physiology-Renal Physiology*.
430 2012;302(12):F1537-F1544.
- 431 38. Kresta JY, Oliver JM, Jagim AR, et al. Effects of 28 days of beta-alanine and creatine
432 supplementation on muscle carnosine, body composition and exercise performance in
433 recreationally active females. *Journal of the International Society of Sports Nutrition*.
434 2014;11(1):55.
- 435 39. Kendrick IP, Harris RC, Kim HJ, et al. The effects of 10 weeks of resistance training combined
436 with β -alanine supplementation on whole body strength, force production, muscular
437 endurance and body composition. *Amino Acids*. 2008;34(4):547-554.
- 438 40. Regazzoni L, de Courten B, Garzon D, et al. A carnosine intervention study in overweight
439 human volunteers: bioavailability and reactive carbonyl species sequestering effect.
440 *Scientific reports*. 2016;6:27224.
- 441 41. Meerwaldt R, Links T, Zeebregts C, Tio R, Hillebrands J-L, Smit A. The clinical relevance of
442 assessing advanced glycation endproducts accumulation in diabetes. *Cardiovascular*
443 *Diabetology*. 2008;7(1):29.
- 444 42. de Courten B, de Courten MP, Soldatos G, et al. Diet low in advanced glycation end products
445 increases insulin sensitivity in healthy overweight individuals: a double-blind, randomized,
446 crossover trial. *Am J Clin Nutr*. 2016;103(6):1426-1433.
- 447 43. Reddy VP, Garrett MR, Perry G, Smith MA. Carnosine: A Versatile Antioxidant and
448 Antiglycating Agent. *Science of Aging Knowledge Environment*. 2005;2005(18):pe12-pe12.
- 449 44. Hipkiss AR, Chana H. Carnosine Protects Proteins against Methylglyoxal-Mediated
450 Modifications. *Biochemical and Biophysical Research Communications*. 1998;248(1):28-32.
- 451 45. Maillard LC. Action des acides amines sur les sucres: formation des melanoidines par voie
452 methodique. *CR Acad Sci*. 1912;154:66-68.
- 453 46. Hobart LJ, Seibel I, Yeargans GS, Seidler NW. Anti-crosslinking properties of carnosine:
454 Significance of histidine. *Life Sciences*. 2004;75(11):1379-1389.
- 455 47. Brownlee M, Pongor S, Cerami A. Covalent attachment of soluble proteins by
456 nonenzymatically glycosylated collagen. Role in the in situ formation of immune complexes.
457 *The Journal of experimental medicine*. 1983;158(5):1739-1744.
- 458 48. Baye E, Ukropec J, De Courten MP, et al. Effect of carnosine supplementation on the plasma
459 lipidome in overweight and obese adults: a pilot randomised controlled trial. 2017;7(1):1-7.
- 460 49. Menon K, Marquina C, Hoj P, Liew D, Mousa A, de Courten B. Carnosine and histidine-
461 containing dipeptides improve dyslipidemia: a systematic review and meta-analysis of
462 randomized controlled trials. *Nutrition Reviews*. 2020;78(11):939-951.

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481


482

483 **Figure legends:**

484 **Figure 1:** Study flow diagram

485 **Figure 2:** Glucose levels after oral glucose tolerance test at baseline and after 14-week intervention


486 by intervention group.




487

488 **Figure 1:** Study flow diagram

489 **Figure 2:** : Glucose levels (A) and Insulin level (B) after oral glucose tolerance test at baseline and after 14-week intervention by intervention group.





491

492



493

494

495

496 Figure 3: Glucose response after OGTT per participant. Bars denote Mean and SD.

497



498

499 Table 1: Baseline characteristics of participants

	Placebo (n=23)		Carnosine (n=20)	
Age – years, (median [IQR])	52 [28.4 – 65.3]		53.8 [30.1 – 66.3]	
Female, (n [%])	7 [30%]		6 [30%]	
Pre-diabetic/Diabetic	11/12		11/9	
Treated with Metformin	9		8	
	Mean	SD	Mean	SD
Weight (kg)	81.8	14.5	88.4	23.8
Height (cm)	169.0	10.3	172.3	12.3
Waist Circumference (cm)	99.0	8.8	103.3	14.7
Hip Circumference (cm)	102.5	7.9	105.7	15.1
Glucose - 0mins (mmol/L)	6.4	1.1	6.4	1.1
Glucose - 30mins (mmol/L)	9.6	1.3	10.3	2.3
Glucose - 60mins (mmol/L)	12.1	2.1	13.0	2.4
Glucose - 90mins (mmol/L)	12.3	2.7	13.3	3.5
Glucose - 120mins (mmol/L)	11.9	3.0	12.0	3.5
Glucose AUC	43.2	7.5	45.8	9.792
Insulin - 0 mins (mIU/ml)	9.7	5.7	14.6	19.3
Insulin - 30 mins (mIU/ml)	32.7	30.3	34.4	17.3
Insulin - 60 mins (mIU/ml)	41.8	26.9	67.5	58.0
Insulin - 90 mins (mIU/ml)	56.1	42.3	96.5	92.0
Insulin - 120 mins (mIU/ml)	70.9	64.5	104.0	111.8
Insulin AUC	159.1	113.3	257.5	216.6
HbA1c (%)	6.7	0.8	6.5	0.6
HOMA-IR	2.7	1.7	4.1	5.3
HOMA-S	51.7	37.6	61.4	101.8

HOMA- β	80.8	63.6	118.8	173.3
---------------------------------	------	------	-------	-------

500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530

Table 2: Baseline and follow-up values and changes in anthropometric, body composition and metabolic measures after 14 weeks of supplementation

	Baseline±S D	Follow- up±SD	Baseline±S D	Follow-Up±SD	Between group mean change*	Between group p- value
Weight(kg)	81.8±14.5	81.5±14.7	88.4±23.8	88.7±24.3	0.012	0.6
BMI (kg/m²)	28.5±3.7	28.4±3.6	29.8±4.9	30.2±4.8	-0.74	0.048
Waist Circumference (cm)	99.0±8.8	96.87±7.8	103.3±14.7	103.8±16.0	-1.59	0.2
Waist to hip ratio (WHR)	0.97±0.06	0.97±0.07	0.98±0.1	0.97±0.08	0.01	0.6
Fat mass (kg)	28.5±7.0	28.0±7.26	33.4±11.7	32.8±10.9	-0.47	0.3
Body fat (%)	35.6±6.7	35.13±6.9	37.01±7.9	36.8±7.6	-0.31	0.4
Fat free mass (kg)	51.8±11.7	51.9±11.7	53.1±13.8	53.2±12.7	-0.27	0.5
Calf muscle density (mg/cm³) †	86.0±2.9	85.5±4.0	86.3±5.04	86.2±5.04	-0.74	0.2
Glucose - 0 minutes (mmol/L)	6.4±1.1	6.3±1.2	6.4±1.1	6.2±1.3	0.08	0.7
Glucose -30 minutes (mmol/L)	9.6±1.3	9.6±2.2	10.3±2.3	10.2±2.3	0.02	1.0
Glucose -60 minutes (mmol/L)	12.1±2.1	11.6±2.7	13.0±2.4	12.1±2.7	0.42	0.5
Glucose - 90 minutes (mmol/L)	12.3±2.7	12.2±2.9	13.3±3.5	11.7±3.05	1.31	0.02
Glucose - 120 minutes (mmol/L)	11.9±3.0	11.9±3.0	12.0±3.5	10.6±4.1	1.60	0.02
Glucose AUC	43.2±7.5	43.03±9.4	45.8±9.8	42.4±9.9	3.19	0.04
Insulin - 0 minutes (mIU/ml)	9.7±5.7	9.1±4.6	14.6±19.3	10.3±6.8	0.06	1.0
Insulin - 30 minutes (mIU/ml)	32.7±30.3	35.5±42.1	34.4±17.3	34.2±19.6	4.03	0.5
Insulin - 60 minutes (mIU/ml)	41.8±26.9	42.6±30.9	67.5±58.0	58.9±64.3	4.25	0.7
Insulin - 90 minutes (mIU/ml)	56.1±42.3	52.8±39.2	96.5±92.0	91.3±104.4	3.59	0.7
Insulin - 120 minutes (mIU/ml)	70.9±64.5	62.6±42.8	104.0±111.8	68.1±65.0	13.9	0.1
Insulin AUC	159.1±2.7	165.1±123.6	257.5±216.6	217.0±197.0	31.63	0.2
HbA1c (%)	6.7±0.8	6.72±1.14	6.5±0.6	6.7±1.1	-0.18	0.4
HOMA-IR	2.7±1.7	2.52±1.35	4.1±5.3	2.7±1.6	0.11	0.8
HOMA-S(%)	51.7±37.6	51.9±29.1	61.4±101.8	161.4±501.1	-116.2	0.3
HOMA- β	80.8±63.6	86.2±108.4	118.8±173.3	140.1±217.8	-26.2	0.7

† n=25; Placebo (n=13) & Carnosine (n=12) *Mean change in Carnosine group – Mean change in Placebo
 BMI (body mass index); HOMA-IR (homeostatic model assessment – insulin resistance); HOMA-S% (homeostatic model assessment – insulin secretion); HOMA-β (homeostatic model assessment – beta cell function); AUC (area under the curve). All analysis between group were also adjusted for diabetic status, obesity status, metformin use, age and sex.

Table 3: Sensitivity analysis of glucose and insulin results, through multiple imputation of missing results, and resulting ANCOVA. Five imputations were used with pooled means and standard errors, and the resulting p-value ranges provided.

Variable	Pooled imputed mean estimates (Std Error)		Range of imputed p-values
Glucose - 0 minutes (mmol/L)	<i>Placebo</i>	6.23 (0.96)	0.19-0.97
	<i>Carnosine</i>	6.21 (0.71)	
Glucose -30 minutes (mmol/L)	<i>Placebo</i>	10.25 (0.63)	0.25-0.99
	<i>Carnosine</i>	9.86 (0.55)	
Glucose -60 minutes (mmol/L)	<i>Placebo</i>	11.90 (0.80)	0.18-0.88
	<i>Carnosine</i>	11.66 (0.55)	
Glucose - 90 minutes (mmol/L)	<i>Placebo</i>	12.69 (0.46)	0.010-0.018
	<i>Carnosine</i>	11.31 (0.41)	
Glucose - 120 minutes (mmol/L)	<i>Placebo</i>	12.05 (0.53)	0.010-0.023
	<i>Carnosine</i>	10.56 (0.48)	
Glucose AUC	<i>Placebo</i>	44.06 (1.03)	0.024-0.055
	<i>Carnosine</i>	41.12 (1.05)	
Insulin - 0 minutes (mIU/ml)	<i>Placebo</i>	9.68 (1.12)	0.68-0.96
	<i>Carnosine</i>	9.80 (1.20)	
Insulin - 30 minutes (mIU/ml)	<i>Placebo</i>	33.52 (9.68)	0.08-0.76
	<i>Carnosine</i>	21.78 (13.68)	
Insulin - 60 minutes (mIU/ml)	<i>Placebo</i>	49.03 (9.65)	0.34-0.86
	<i>Carnosine</i>	45.69 (9.33)	
Insulin - 90 minutes (mIU/ml)	<i>Placebo</i>	63.82 (10.24)	0.18-0.81
	<i>Carnosine</i>	77.44 (11.55)	
Insulin - 120 minutes (mIU/ml)	<i>Placebo</i>	69.08 (7.94)	0.086-0.82
	<i>Carnosine</i>	63.15 (11.17)	
Insulin AUC	<i>Placebo</i>	185.32 (19.84)	0.42-0.99
	<i>Carnosine</i>	181.87 (21.61)	